Is Gatorade Bad For You? - Verywell Health

About 122,000 cases of the popular sports drink Gatorade have been voluntarily recalled across 37 US states due to their having “undeclared” food dye, according to an official federal notice. The varieties of the drink involved in the notice include 28oz bottles of Gatorade Lemon Lime, Lime Zero, Orange and Gatorade Orange Zero, the notice said. Gatorade’s manufacturer – the soda giant PepsiCo – initiated its recall on 25 September, said the advisory, which was posted on the US Food and Drug Administration (FDA)’s website. The notice said the recall was considered class II, implying “a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote”, according to the FDA. “Undeclared Yellow No 6 and/or Yellow No 5” dyes were listed in the FDA notice as the “reason for recall” for people who are potentially sensitive to them. PepsiCo did not immediately respond to a request for comment from the Guardian.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.